SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 3 filers reported holding SYROS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $186,000 | – | 193,483 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARCH Venture Management, LLC | 200,000 | $1,768,000 | 8.83% |
Samsara BioCapital, LLC | 1,407,949 | $11,608,000 | 3.24% |
Flagship Pioneering Inc. | 2,938,494 | $25,976,000 | 0.72% |
ARK Investment Management | 11,212,506 | $99,119,000 | 0.59% |
Portolan Capital Management | 450,861 | $3,986,000 | 0.45% |
Capital Impact Advisors, LLC | 168,600 | $1,490,000 | 0.44% |
Nikko Asset Management Americas, Inc. | 4,182,346 | $36,261,000 | 0.32% |
Sio Capital Management, LLC | 166,780 | $1,474,000 | 0.29% |
Virtus ETF Advisers LLC | 34,835 | $308,000 | 0.16% |
Artal Group S.A. | 465,500 | $4,115,000 | 0.10% |